LAB eN², which aims to nurture early research from academic institutions into novel therapeutics, has selected its first three projects to move forward in the program from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center.
Evotec and Novo Nordisk launched LAB eN² in September 2023 with four academic institutions, Harvard University, Mass General Brigham, Yale School of Medicine, and Beth Israel Deaconess Medical Center. Under an expansion program, researchers from Boston Children’s Hospital, Boston University, Johns Hopkins University, Joslin Diabetes Center, and Icahn Mount Sinai can now also apply to LAB eN².
Leveraging access to Evotec’s integrated R&D platform and Novo Nordisk’s deep disease understanding, LAB eN² provides funding to design a drug discovery program and identify a therapeutic candidate across a range of therapeutic modalities. The program also offers scientific expertise and technology to help advance product concepts through preclinical proof of concept, at which point successful therapeutic product candidates may be selected by Novo Nordisk for further investment and development.
Full story: Novo Nordisk and Evotec Select First Three LAB eN² Drug Discovery Projects
